Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients

A. Daumas (1) , Jérémy Magalon (2) , E. Jouve (3) , R. Truillet (3) , D. Casanova (4) , L. Giraudo , J. Veran , Audrey Benyamine (5, 2) , Francoise Dignat-George (2) , G. Magalon (6, 3) , Florence Sabatier (2) , Brigitte Granel (2)

1 Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon)
2 VRCM - Vascular research center of Marseille
3 CIC-CPCET
4 LA CONCEPTION - Hôpital de la Conception [CHU - APHM]
5 MARSEILLE - Med Int - Service de Médecine Interne
6 Service de chirurgie de la main, chirurgie plastique et réparatrice des membres

Introduction: Hand involvement confers a substantial handicap in work and daily activities in patients with Systemic sclerosis (SSc). Autologous adipose-derived stromal vascular fraction is as an easily accessible source of cells with regenerative effects. We previously performed a phase I open-label clinical trial (NTC01813279) assessing the safety of subcutaneous injection of autologous adipose-derived stromal vascular fraction. Six and 12-month data have been reported. As patients were followed in our medical centre, we report their longer-term outcome beyond the end of the trial. Patients and method: Twelve females, mean age 54.5 ± 10.3 years, initially enrolled in the clinical trial were assessed during a scheduled medical care, which took place between 22 and 30 months after treatment. Results: Multiple patient-reported outcomes showed sustained improvement, in comparison with the assessment performed just before surgery: 62.5% in the Cochin Hand Function Scale, 51.1% in the Scleroderma Health Assessment Questionnaire, 33.1% in hand pain, and 88.3% in the Raynaud Condition Score. A decrease in the number of digital ulcers number was noted. Mobility, strength and fibrosis of the hand also showed improvement. None of the 8 patients who had previously received iloprost infusion required new infusion. Conclusion: Despite the limits of an open label study, the data are in favour of the long-term safety of the adipose-derived stromal vascular fraction injection. Two randomized double blind, placebo-controlled trials of this therapeutic agent are ongoing in the USA (NCT02396238) and in France (NCT02558543) and will help determine the place of this innovative therapy for SSc patients.

Domaines: Médecine humaine et pathologie

A. Daumas, Jérémy Magalon, E. Jouve, R. Truillet, D. Casanova, et al.. Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients. Current Research in Translational Medicine, 2017, 65 (1), pp.40-43. ⟨10.1016/j.retram.2016.10.006⟩. ⟨hal-01792172⟩